CD4+CD25+ Regulatory T Cells Inhibit Natural Killer Cell Hepatocytotoxicity of Hepatitis B Virus Transgenic Mice via Membrane-Bound TGF-β and OX40

Journal of Innate Immunity

Volumn 8, Issue 1, 2016, Pages 30-42

  Chen, Yongyan ^a   Sun, Rui ^a,b   Wu, Xunyao ^a   Cheng, Min ^a   Wei, Haiming ^a,b   Tian, Zhigang ^a,b  

^a UNIVERSITY OF SCIENCE AND TECHNOLOGY OF CHINA   (China)

^b UNIVERSITY OF SCIENCE AND TECHNOLOGY OF CHINA   (China)

Author keywords

Acute liver injury; Concanavalin A; Hepatitis B virus; Natural killer cell; Treg cell

Indexed keywords

CONCANAVALIN A; OX40 LIGAND; TRANSFORMING GROWTH FACTOR BETA; CD134 ANTIGEN; INTERLEUKIN 2 RECEPTOR ALPHA; KLRK1 PROTEIN, MOUSE; MEMBRANE PROTEIN; NATURAL KILLER CELL LECTIN LIKE RECEPTOR SUBFAMILY K; TNFRSF4 PROTEIN, MOUSE; TNFSF4 PROTEIN, MOUSE; TUMOR NECROSIS FACTOR;

ADOPTIVE TRANSFER; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CD4+ CD25+ T LYMPHOCYTE; CELL CONTACT; CHRONIC HEPATITIS B; HEPATITIS B VIRUS; LIVER INJURY; LIVER TOXICITY; MALE; MOUSE; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; REGULATORY T LYMPHOCYTE; UPREGULATION; ANIMAL; C57BL MOUSE; CELL MEMBRANE; CYTOTOXICITY; DISEASE MODEL; GENETICS; IMMUNOLOGICAL TOLERANCE; IMMUNOLOGY; LIVER; LYMPHOCYTE ACTIVATION; PATHOLOGY; TRANSGENIC MOUSE;

ADOPTIVE TRANSFER; ANIMALS; CELL MEMBRANE; CONCANAVALIN A; CYTOTOXICITY, IMMUNOLOGIC; DISEASE MODELS, ANIMAL; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; IMMUNE TOLERANCE; INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT; KILLER CELLS, NATURAL; LIVER; LYMPHOCYTE ACTIVATION; MALE; MEMBRANE GLYCOPROTEINS; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; NK CELL LECTIN-LIKE RECEPTOR SUBFAMILY K; RECEPTORS, OX40; T-LYMPHOCYTES, REGULATORY; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTORS;

EID: 84955629256     PISSN: 1662811X     EISSN: 16628128     Source Type: Journal    
DOI: 10.1159/000431150     Document Type: Article

References (34)

1. Chen Y, Wei H, Sun R, Dong Z, Zhang J, Tian Z: Increased susceptibility to liver injury in hepatitis B virus transgenic mice involves NKG2D-ligand interaction and natural killer cells. Hepatology 2007;46:706-715.
2. Wei HX, Chuang YH, Li B, Wei H, Sun R, Moritoki Y, Gershwin ME, et al. CD4+CD25+ Foxp3+ regulatory T cells protect against T cell-mediated fulminant hepatitis in a TGF-β-dependent manner in mice. J Immunol 2008;181:7221-7229.
3. Erhardt A, Biburger M, Papadopoulos T, Tiegs G: IL-10, regulatory T cells, and Kupffer cells mediate tolerance in concanavalin A-induced liver injury in mice. Hepatology 2007;45:475-485.
4. Miethke AG, Saxena V, Shivakumar P, Sabla GE, Simmons J, Chougnet CA: Post-natal paucity of regulatory T cells and control of NK cell activation in experimental biliary atresia. J Hepatol 2010;52:718-726.
5. Xu D, Fu J, Jin L, Zhang H, Zhou C, Zou Z, Zhao JM, et al. Circulating and liver resident CD4+CD25+ regulatory T cells actively influence the antiviral immune response and disease progression in patients with hepatitis B. J Immunol 2006;177:739-747.
6. Stoop JN, van der Molen RG, Baan CC, van der Laan LJ, Kuipers EJ, Kusters JG, Janssen HL: Regulatory T cells contribute to the impaired immune response in patients with chronic hepatitis B virus infection. Hepatology 2005;41:771-778.
7. Nan XP, Zhang Y, Yu HT, Sun RL, Peng MJ, Li Y, Su WJ, et al. Inhibition of viral replication downregulates CD4+CD25high regulatory T cells and programmed death-ligand 1 in chronic hepatitis B. Viral Immunol 2012;25:21-28.
8. Zhang JY, Song CH, Shi F, Zhang Z, Fu JL, Wang FS: Decreased ratio of Treg cells to Th17 cells correlates with HBV DNA suppression in chronic hepatitis B patients undergoing entecavir treatment. PLoS One 2010;5:e13869.
9. Stross L, Gunther J, Gasteiger G, Asen T, Graf S, Aichler M, Esposito I, et al. Foxp3+ regulatory T cells protect the liver from immune damage and compromise virus control during acute experimental hepatitis B virus infection in mice. Hepatology 2012;56:873-883.
10. Piconese S, Timperi E, Pacella I, Schinzari V, Tripodo C, Rossi M, Guglielmo N, et al. Human OX40 tunes the function of regulatory T cells in tumor and nontumor areas of hepatitis C virus-infected liver tissue. Hepatology 2014;60:1494-1507.
11. Xiao X, Gong W, Demirci G, Liu W, Spoerl S, Chu X, Bishop DK, et al. New insights on OX40 in the control of T cell immunity and immune tolerance in vivo. J Immunol 2012;188:892-901.
12. Griseri T, Asquith M, Thompson C, Powrie F: OX40 is required for regulatory T cell-mediated control of colitis. J Exp Med 2010;207:699-709.
13. Vu MD, Xiao X, Gao W, Degauque N, Chen M, Kroemer A, Killeen N, et al. OX40 costimulation turns off Foxp3+ Tregs. Blood 2007;110:2501-2510.
14. Gri G, Piconese S, Frossi B, Manfroi V, Merluzzi S, Tripodo C, Viola A, et al. CD4+CD25+ regulatory T cells suppress mast cell degranulation and allergic responses through OX40-OX40L interaction. Immunity 2008;29:771-781.
15. Piconese S, Valzasina B, Colombo MP: OX40 triggering blocks suppression by regulatory T cells and facilitates tumor rejection. J Exp Med 2008;205:825-839.
16. Ruby CE, Yates MA, Hirschhorn-Cymerman D, Chlebeck P, Wolchok JD, Houghton AN, Offner H, et al. Cutting edge: OX40 agonists can drive regulatory T cell expansion if the cytokine milieu is right. J Immunol 2009;183:4853-4857.
17. Takeda K, Hayakawa Y, van Kaer L, Matsuda H, Yagita H, Okumura K: Critical contribution of liver natural killer T cells to a murine model of hepatitis. Proc Natl Acad Sci USA 2000;97:5498-5503.
18. Jaruga B, Hong F, Sun R, Radaeva S, Gao B: Crucial role of IL-4/STAT6 in T cell-mediated hepatitis: up-regulating eotaxins and IL-5 and recruiting leukocytes. J Immunol 2003;171:3233-3244.
19. Ogasawara K, Hamerman JA, Hsin H, Chikuma S, Bour-Jordan H, Chen T, Pertel T, et al. Impairment of NK cell function by NKG2D modulation in NOD mice. Immunity 2003;18:41-51.
20. Shevach EM: Regulatory T cells in autoimmmunity. Annu Rev Immunol 2000;18:423-449.
21. Sakaguchi S: Naturally arising Foxp3-expressing CD25+CD4+ regulatory T cells in immunological tolerance to self and non-self. Nat Immunol 2005;6:345-352.
22. Ralainirina N, Poli A, Michel T, Poos L, Andres E, Hentges F, Zimmer J: Control of NK cell functions by CD4+CD25+ regulatory T cells. J Leukoc Biol 2007;81:144-153.
23. Pedroza-Pacheco I, Madrigal A, Saudemont A: Interaction between natural killer cells and regulatory T cells: perspectives for immunotherapy. Cell Mol Immunol 2013;10:222-229.
24. Barao I, Hanash AM, Hallett W, Welniak LA, Sun K, Redelman D, Blazar BR, et al. Suppression of natural killer cell-mediated bone marrow cell rejection by CD4+CD25+ regulatory T cells. Proc Natl Acad Sci USA 2006;103:5460-5465.
25. Colonna M: NK cells: new issues and challenges. Preface. Eur J Immunol 2008;38:2927-2929.
26. Busca A, Kumar A: Innate immune responses in hepatitis B virus (HBV) infection. Virol J 2014;11:22.
27. Das A, Maini MK: Innate and adaptive immune responses in hepatitis B virus infection. Dig Dis 2010;28:126-132.
28. Toyabe S, Seki S, Iiai T, Takeda K, Shirai K, Watanabe H, Hiraide H, et al. Requirement of IL-4 and liver NK1+ T cells for concanavalin A-induced hepatic injury in mice. J Immunol 1997;159:1537-1542.
29. Vignali DA, Collison LW, Workman CJ: How regulatory T cells work. Nat Rev Immunol 2008;8:523-532.
30. Chen Y, Wei H, Sun R, Tian Z: Impaired function of hepatic natural killer cells from murine chronic HBsAg carriers. Int Immunopharmacol 2005;5:1839-1852.
31. Cai L, Zhang Z, Zhou L, Wang H, Fu J, Zhang S, Shi M, et al. Functional impairment in circulating and intrahepatic NK cells and relative mechanism in hepatocellular carcinoma patients. Clin Immunol 2008;129:428-437.
32. Ghiringhelli F, Menard C, Terme M, Flament C, Taieb J, Chaput N, Puig PE, et al. CD4+CD25+ regulatory T cells inhibit natural killer cell functions in a transforming growth factor-β-dependent manner. J Exp Med 2005;202:1075-1085.
33. Smyth MJ, Teng MW, Swann J, Kyparissoudis K, Godfrey DI, Hayakawa Y: CD4+CD25+ T regulatory cells suppress NK cell-mediated immunotherapy of cancer. J Immunol 2006;176:1582-1587.
34. Vilarinho S, Ogasawara K, Nishimura S, Lanier LL, Baron JL: Blockade of NKG2D on NKT cells prevents hepatitis and the acute immune response to hepatitis B virus. Proc Natl Acad Sci USA 2007;104:18187-18192.